Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03984240
Other study ID # 81701038
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2020
Est. completion date December 31, 2023

Study information

Verified date July 2023
Source Beijing Tiantan Hospital
Contact Nan LIN, MD, PhD
Phone 8610-13810108927
Email linnan127@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It has been shown through functional MRI (Magnetic Resonance Imaging) that patients with gliomas in eloquent areas have compensated neurological function by virtue of brain post-injury reorganization. Our previous clinical research found that mild sedation could induce and/or exacerbate neurological deficits, especially in limb motor and ataxia function, in these patients presumably by impairing functional compensation,. Nevertheless it is still very unclear how mild sedation affects sensorimotor networks in brains where reorganization may be present. Since eloquent area glioma patients are frequently subjected to sedation, anesthetics, and neurological examinations perioperatively, it is important to investigate how mild sedation interacts with motor network reorganization and functional compensation. Our research in patients with eloquent area gliomas will utilize neurological evaluations and multimodal MRI to explore the changes in brain upper limb' motor network reorganization after mild sedation by different sedatives-anesthetics. The neurological evaluations include sensorimotor function scale and testing tool. Multimodal MRI consists of 3-dimentional structure, blood oxygen-level dependent for cortical activation and diffusion tensor imaging for subcortical conduction. The data from the clinical testing and functional MRI will be processed and analyzed along with other relevant clinical information. This research will answer the question of how mild sedation affects upper limb motor function networks in brains with eloquent area gliomas. This new information will help optimize perioperative anesthetic and sedative choice for patients with eloquent area gliomas.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria: - Age between 25 to 60 years old; - Diagnosed as intracranial eloquent glioma by MRI, or healthy volunteer without any intracranial disease; - Without history of chronic diseases; - Without internal and/external metal object; - Education background is beyond high school; - Right handedness Exclusion Criteria: - Unable to cooperate the neurologic function evaluation; - Neuropsychiatric disorders and/or taking antipsychotic medications; - Drug and/or alcohol abuse; - Receiving longterm sedatives and/or analgesics; - Pregnant and/or lactation period patients; - Present severe cardiovascular diseases; - Having claustrophobia; - Body mass index equal or more than 35 kg/m2; - Anticipated difficult airway; - History of severe obstructive sleep apnea; - History of reflux

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Midazolam
Participant will be sedated by midazolam.
Dexmedetomidine
Participant will be sedated by dexmedetomidine.

Locations

Country Name City State
China Beijing Tiantan Hospital, Capital Medical University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brain network connectivity will use fMRI and DTI 2 hours following sedation
Secondary upper limb's motor function will use 9-hole peg test and motor/sensory function evaluation 2 hours following sedation
Secondary pathological diagnose of glioma the detailed type of glioma and WHO glioma grade 2 weeks after surgery completion
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05593809 - Single Photon Emission Computed Tomography/Computed Tomography With Pentavalent 99mTc Dimercaptosuccinic Acid in Patients With Brain Glioma; Correlation With IDH Mutation
Not yet recruiting NCT05595863 - Correlation Between SPECT/CT and IDH Mutation in Brain Glioma
Completed NCT03042416 - 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Phase 3